Stone X Group Inc. Acurx Pharmaceuticals, Inc. Transaction History
Stone X Group Inc.
- $2.29 Trillion
- Q3 2025
Shares
1 transactions
Others Institutions Holding ACXP
# of Institutions
6Shares Held
36.4KCall Options Held
100Put Options Held
0-
Black Rock Inc. New York, NY27.5KShares$116,0620.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ7.58KShares$31,9960.0% of portfolio
-
Cutler Group LP1.2KShares$5,0640.0% of portfolio
-
Semmax Financial Advisors Inc. Winston Salem, NC153Shares$6450.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$0100.0% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $48.8M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...